Published in APMIS on December 01, 2007
Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res (2010) 3.04
Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer. Br J Cancer (2009) 1.45
Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. Breast Cancer Res Treat (2013) 1.26
A comprehensive morphological study for basal-like breast carcinomas with comparison to nonbasal-like carcinomas. Diagn Pathol (2012) 1.04
Metastatic breast cancer in a Nigerian tertiary hospital. Afr Health Sci (2011) 0.87
Invasive breast carcinomas in Ghana: high frequency of high grade, basal-like histology and high EZH2 expression. Breast Cancer Res Treat (2012) 0.84
Implementation of a percutaneous core needle biopsy training program: results from the University of Michigan-Komfo Anokye Teaching Hospital breast cancer research partnership. Ann Surg Oncol (2010) 0.79
The prevalence of estrogen receptor-negative breast cancer in Ethiopia. BMC Cancer (2014) 0.79
Basal-like phenotype in a breast carcinoma case series from Sudan: prevalence and clinical/pathological correlations. Patholog Res Int (2011) 0.78
Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration. BMC Cancer (2016) 0.77
Strong Expression of Hypoxia-Inducible Factor-1α (HIF-1α) Is Associated with Axl Expression and Features of Aggressive Tumors in African Breast Cancer. PLoS One (2016) 0.76
Tumor infiltrating leukocyte density is independent of tumor grade and molecular subtype in aggressive breast cancer of Western Kenya. Trop Med Health (2017) 0.75
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res (2004) 16.51
Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst (2003) 8.48
A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst (2006) 4.44
EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol (2005) 4.24
Part I: Cancer in Indigenous Africans--burden, distribution, and trends. Lancet Oncol (2008) 3.91
Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res (2009) 3.45
Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A (2008) 3.30
Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A (2009) 3.29
Malignant melanoma--diagnosis, treatment and follow-up in Norway. Tidsskr Nor Laegeforen (2013) 3.21
Cancer survival in Africa, Asia, and Central America: a population-based study. Lancet Oncol (2009) 3.14
Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle (2006) 3.10
Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer (2007) 3.09
Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res (2009) 2.91
Improvement of pathology in sub-Saharan Africa. Lancet Oncol (2013) 2.88
A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res (2007) 2.57
The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res (2004) 2.38
Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet (2011) 2.29
Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-Cancer Registry Match Study. Int J Cancer (2006) 2.25
Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res (2006) 2.10
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res (2009) 2.04
Early detection of breast cancer based on gene-expression patterns in peripheral blood cells. Breast Cancer Res (2005) 2.00
Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin Cancer Res (2003) 1.96
A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev (2005) 1.74
Independent prognostic impact of lymphatic vessel density and presence of low-grade lymphangiogenesis in cutaneous melanoma. Clin Cancer Res (2003) 1.74
Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Mol Cancer Ther (2006) 1.64
Genome-wide profiling of histone h3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis. PLoS One (2009) 1.54
Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res (2005) 1.51
Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clin Cancer Res (2005) 1.49
Antibodies against malaria and Epstein-Barr virus in childhood Burkitt lymphoma: a case-control study in Uganda. Int J Cancer (2008) 1.49
Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol (2004) 1.39
The sero-epidemiology of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in adults with cancer in Uganda. Int J Cancer (2003) 1.34
Secondary breast cancer: a 5-year population-based study with review of the literature. APMIS (2009) 1.33
Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression. Int J Oncol (2004) 1.31
Epithelial to mesenchymal transition of a primary prostate cell line with switches of cell adhesion modules but without malignant transformation. PLoS One (2008) 1.27
Part II: Cancer in Indigenous Africans--causes and control. Lancet Oncol (2008) 1.27
Risk factors for Kaposi's sarcoma: a case-control study of HIV-seronegative people in Uganda. Int J Cancer (2003) 1.24
Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis. FASEB J (2006) 1.21
Lack of estrogen receptor-α is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma. Clin Cancer Res (2013) 1.21
Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid (2006) 1.21
Vascular proliferation is important for clinical progress of endometrial cancer. Cancer Res (2006) 1.19
Contribution of HIV infection to mortality among cancer patients in Uganda. AIDS (2013) 1.19
Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer. Clin Cancer Res (2011) 1.19
Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. BMC Cancer (2010) 1.18
A variant in FTO shows association with melanoma risk not due to BMI. Nat Genet (2013) 1.17
Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. Eur J Cancer (2013) 1.17
Tumor-vascular interactions and tumor dormancy. APMIS (2008) 1.16
GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival. Am J Obstet Gynecol (2008) 1.15
Heterogeneity among Mycobacterium ulcerans isolates from Africa. Emerg Infect Dis (2006) 1.13
Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. Proc Natl Acad Sci U S A (2012) 1.12
Biologic markers in endometrial cancer treatment. APMIS (2009) 1.12
Prosaposin inhibits tumor metastasis via paracrine and endocrine stimulation of stromal p53 and Tsp-1. Proc Natl Acad Sci U S A (2009) 1.12
Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer. Cancer Res (2009) 1.11
NATH, a novel gene overexpressed in papillary thyroid carcinomas. Oncogene (2002) 1.09
High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma. Gynecol Oncol (2012) 1.06
Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma. Cancer (2002) 1.06
TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis. APMIS (2009) 1.06
Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J Med Genet (2013) 1.04
Interphase fluorescence in situ hybridization for detection of 8q24/MYC breakpoints on routine histologic sections: validation in Burkitt lymphomas from three geographic regions. Genes Chromosomes Cancer (2004) 1.04
Tumor necrosis is associated with increased alphavbeta3 integrin expression and poor prognosis in nodular cutaneous melanomas. BMC Cancer (2008) 1.03
Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers. Cancer Res (2002) 1.03
Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers. PLoS One (2013) 1.02
Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts. J Magn Reson Imaging (2013) 1.02
Expression of EGFR and c-kit is associated with the basal-like phenotype in breast carcinomas of African women. APMIS (2008) 1.02
The roles of national cancer research institutions in evolving a comprehensive cancer control program in a developing country: experience from Uganda. Oncology (2009) 1.01
A 'giant' intraluminal lipoma presenting with intussusception in an adult: a case report. J Med Case Rep (2012) 1.01
A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation. Genes Chromosomes Cancer (2005) 1.01
Loss of BMI-1 expression is associated with clinical progress of malignant melanoma. Mod Pathol (2008) 1.00
Factors associated with carcinoma of the oesophagus at Mulago Hospital, Uganda. Afr Health Sci (2008) 1.00
Expression of bFGF/FGFR-1 and vascular proliferation related to clinicopathologic features and tumor progress in localized prostate cancer. Virchows Arch (2005) 0.97
African Burkitt lymphoma: age-specific risk and correlations with malaria biomarkers. Am J Trop Med Hyg (2011) 0.97
High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition. Clin Cancer Res (2013) 0.97
Prognostic importance of the mitotic marker phosphohistone H3 in cutaneous nodular melanoma. J Invest Dermatol (2012) 0.94
Efficient in vivo vascularization of tissue-engineering scaffolds. J Tissue Eng Regen Med (2010) 0.94
Bone marrow-derived Gr1+ cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1. Cancer Discov (2013) 0.94
Polymorphisms in hormone metabolism and growth factor genes and mammographic density in Norwegian postmenopausal hormone therapy users and non-users. Breast Cancer Res (2012) 0.92
Altered expression of cell cycle regulators Cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas. Int J Oncol (2004) 0.92
Lipocalin 2 expression is associated with aggressive features of endometrial cancer. BMC Cancer (2012) 0.92
Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas. Am J Obstet Gynecol (2006) 0.92
Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa. J Clin Oncol (2009) 0.92
Endothelial microvascular networks affect gene-expression profiles and osteogenic potential of tissue-engineered constructs. Stem Cell Res Ther (2013) 0.91
MSI-low, a real phenomenon which varies in frequency among cancer types. J Pathol (2003) 0.91
BK virus and cancer in Uganda. Eur J Cancer Prev (2006) 0.91
Reactive lymphadenopathy in Ugandan patients and its relationship to EBV and HIV infection. APMIS (2009) 0.91
Vascular proliferation is increased in basal-like breast cancer. Breast Cancer Res Treat (2011) 0.91
Increased expression of VEGF-receptors (FLT-1, KDR, NRP-1) and thrombospondin-1 is associated with glomeruloid microvascular proliferation, an aggressive angiogenic phenotype, in malignant melanoma. Angiogenesis (2003) 0.90
In vivo MRI and histopathological assessment of tumor microenvironment in luminal-like and basal-like breast cancer xenografts. J Magn Reson Imaging (2011) 0.90
Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas. APMIS (2003) 0.90
Deoxyribonucleic acid ploidy in endometrial carcinoma: a reproducible and valid prognostic marker in a routine diagnostic setting. Am J Obstet Gynecol (2009) 0.90
Reprogramming of cell junction modules during stepwise epithelial to mesenchymal transition and accumulation of malignant features in vitro in a prostate cell model. Exp Cell Res (2010) 0.90
Loss of hMSH2 and hMSH6 expression is frequent in sporadic endometrial carcinomas with microsatellite instability: a population-based study. Clin Cancer Res (2002) 0.89
Low frequency of BRAF and CDKN2A mutations in endometrial cancer. Int J Cancer (2005) 0.89
Integration of HIV and cervical cancer screening perceptions and preferences of communities in Uganda. BMC Womens Health (2015) 0.89
Helicobacter pylori and cancer among adults in Uganda. Infect Agent Cancer (2006) 0.89
Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer. Cancer (2013) 0.89
WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence. Clin Cancer Res (2008) 0.88